These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 31152591)

  • 1. Reply.
    Allen AM; Talwalkar JA; McCoy RG
    Hepatology; 2019 Oct; 70(4):1493-1494. PubMed ID: 31152591
    [No Abstract]   [Full Text] [Related]  

  • 2. Letter to the Editor: Suggestions for Rational Management of Nonalcoholic Fatty Liver Disease.
    Luo L; Zou H; Zheng S; Duan Z; Chen Y
    Hepatology; 2019 Oct; 70(4):1492-1493. PubMed ID: 31152594
    [No Abstract]   [Full Text] [Related]  

  • 3. Economic and Quality-of-Life Implications of Non-Alcoholic Fatty Liver Disease.
    Younossi ZM; Henry L
    Pharmacoeconomics; 2015 Dec; 33(12):1245-53. PubMed ID: 26233836
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Authors' reply to letter from Schiøtz et al. on "Use of surgical databases in urogynaecology".
    Abdelrahman A; Moore A; Trochez R
    Int Urogynecol J; 2020 Apr; 31(4):849. PubMed ID: 31776618
    [No Abstract]   [Full Text] [Related]  

  • 5. In Reply to Braunstein.
    Buszek SM; Shaitelman SF
    Int J Radiat Oncol Biol Phys; 2019 Dec; 105(5):1162-1163. PubMed ID: 31748138
    [No Abstract]   [Full Text] [Related]  

  • 6. Z. Slim and S. Bernatsky reply.
    Slim Z; Bernatsky S
    J Rheumatol; 2020 May; 47(5):781. PubMed ID: 32062609
    [No Abstract]   [Full Text] [Related]  

  • 7. Trends in Alcoholic Fatty Liver Disease-Reply.
    Dang K; Wong RJ
    JAMA; 2019 Sep; 322(10):980-981. PubMed ID: 31503304
    [No Abstract]   [Full Text] [Related]  

  • 8. Reply to: "Hepatic fibrosis - and not steatosis - is the main determinant of arterial stiffness in non-alcoholic fatty liver disease".
    Styczyński G; Kalinowski P; Michałowski Ł; Paluszkiewicz R; Ziarkiewicz-Wróblewska B; Zieniewicz K; Tataj E; Szmigielski C; Jędrusik P
    Atherosclerosis; 2019 Nov; 290():224-225. PubMed ID: 31519330
    [No Abstract]   [Full Text] [Related]  

  • 9. Editorial: liver transplantation in patients with non-alcoholic fatty liver disease and obesity-authors' reply.
    Barone M; Viggiani MT; Losurdo G; Principi M; Leandro G; Di Leo A
    Aliment Pharmacol Ther; 2017 Aug; 46(4):460-461. PubMed ID: 28707799
    [No Abstract]   [Full Text] [Related]  

  • 10. Reply to "Statin treatment for non-alcoholic steatohepatitis".
    Dongiovanni P; Pihlajamaki J; Romeo S; Valenti L
    J Hepatol; 2016 Jan; 64(1):242-3. PubMed ID: 26456843
    [No Abstract]   [Full Text] [Related]  

  • 11. Reply-Letter to the Editor-Is liver steatosis diagnostic of non-alcoholic fatty liver disease in patients with hereditary fructose intolerance?
    Aldamiz-Echevarria L; Villate O
    Clin Nutr; 2019 Aug; 38(4):1962. PubMed ID: 31104878
    [No Abstract]   [Full Text] [Related]  

  • 12. Reply to: "Procoagulant imbalance in patients with non-alcoholic fatty liver disease".
    Potze W; Sanyal AJ; Lisman T
    J Hepatol; 2017 Jan; 66(1):250-251. PubMed ID: 27769733
    [No Abstract]   [Full Text] [Related]  

  • 13. Letter: the efficacy of oltipraz in patients with non-alcoholic fatty liver disease has not been confirmed-authors' reply.
    Kim W; Kim YJ
    Aliment Pharmacol Ther; 2017 Jul; 46(2):210. PubMed ID: 28621080
    [No Abstract]   [Full Text] [Related]  

  • 14. Non-alcoholic fatty liver disease concerns with glucokinase activators - Authors' reply.
    Li X; Chen L
    Lancet Diabetes Endocrinol; 2018 Sep; 6(9):685. PubMed ID: 30143186
    [No Abstract]   [Full Text] [Related]  

  • 15. Clinical and Economic Burden of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis.
    Younossi ZM; Henry L; Bush H; Mishra A
    Clin Liver Dis; 2018 Feb; 22(1):1-10. PubMed ID: 29128049
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reply to: "The association between sarcopenia and non-alcoholic fatty liver disease".
    Koo BK; Kim D; Joo SK; Kim JH; Chang MS; Kim BG; Lee KL; Kim W
    J Hepatol; 2017 Jan; 66(1):244-245. PubMed ID: 27743988
    [No Abstract]   [Full Text] [Related]  

  • 17. Letter: use of collagen proportionate area to quantify liver fibrosis and predict clinical outcomes non-alcoholic fatty liver disease-authors' reply.
    Buzzetti E; Tsochatzis EA
    Aliment Pharmacol Ther; 2019 Aug; 50(3):339. PubMed ID: 31313369
    [No Abstract]   [Full Text] [Related]  

  • 18. Reply to: "Non-invasive prediction of oesophageal varices in patients with cirrhosis secondary to non-alcoholic fatty liver disease".
    Petta S; Sebastiani G; de Ledinghen V
    J Hepatol; 2018 Nov; 69(5):1203-1204. PubMed ID: 30193923
    [No Abstract]   [Full Text] [Related]  

  • 19. Reduced impact of renal failure on the outcome of patients with alcoholic liver disease undergoing liver transplantation.
    Cheong J; Galanko JA; Arora S; Cabezas J; Ndugga NJ; Lucey MR; Hayashi PH; Barritt AS; Bataller R
    Liver Int; 2017 Feb; 37(2):290-298. PubMed ID: 27258535
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A brief review on the rising incidence of chronic kidney diseases and non-alcoholic fatty liver disease.
    Nagy J; Kovács T
    Physiol Int; 2019 Dec; 106(4):305-310. PubMed ID: 31906711
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.